chemie.pr-OnVista: ISOTECHNIKA (934786,CA4649041015) - Aktienanalyse - News - Ad-hoc
Isotechnika Presents Positive Data From the Promise Trial of Voclosporin at the American Transplant Congress Call to Discuss Positive PROMISE Trial
Isotechnika Presents Positive Data From the Promise Trial of Voclosporin at the American Transplant Congress
04.06.2008 14:40:05
Isotechnika Inc.: Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. today announces the successful results of the Phase 2b PROMISE trial which were presented by Dr. A. Osama Gaber, an investigator for the PROMISE trial, at the 2008 American Transplant Congress in Toronto, Canada. The presentation detailed the final data confirming the efficacy of Isotechnika's next generation calcineurin inhibitor, voclosporin (ISA247), in de novo kidney transplant ...
Lesen Sie hier weiter... |
Drucken |
PDF
Ähnliche Artikel
- Isotechnika Reports Final Results of the PROMISE Trial
- Isotechnika to Hold Conference Call to Discuss Positive PROMISE Trial
- Drug-Eluting Coronary Stents Utilizing Isotechnika's Lead Drug Receive Approval to Enter Clinical Trials
- Pertuzumab With Herceptin(R) Shows Impressive Results in Women With Advanced HER2-Positive Breast Cancer
- Movetis' Second Most Advanced Product Progresses to Phase IIb Trial Following Positive Results in Cirrhotic Ascites
- COPD Landmark Trial UPLIFT Proves Tiotropium Sustains Lung Function Improvements Over Four Years and Improves Survival Rate
- SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease
- Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
- Coversyl(R) Protects Hypertensive Patients Against New-Onset Diabetes
- Roche to Present Data Showing Progress in Treating Lung, Gastric and Brain Cancers at ESMO
Isotechnika Inc. Aktien | 934786 | CA4649041015 | IKA
Isotechnika Inc.- Isotechnika Presents Positive Data From the Prom Presseportal Isotechnika to hold conference call to discuss positive PROMISE trial
Bankkaufmann - News
Isotechnika Presents Positive Data From the Promise Trial of Voclosporin at the American Transplant Congress of the Phase 2b PROMISE trial whichwere
www.finanznachrichten.de/nachrichten-aktien/<b>isotechnika</b>-de.asp
:: Nachrichten zur ISOTECHNIKA Aktie.:: Alle News zu Ihren Aktien.Isotechnika Presents Positive Data From the Promise Trial of Voclosporin at the American
ots.at: das APA-OTS-Portal für multimediale Presseaussendungen
Isotechnika Presents Positive Data From the Promise Trial of Voclosporin at the American Transplant.Congress at the American Transplant Congress